Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-(2-methylpiperazine-1-sulfonyl)isoquinoline is a synthetic small molecule belonging to the class of N-sulfonylpiperazines and isoquinolines. It is best known as a potent and selective inhibitor of protein kinase C (PKC), with additional inhibitory activity against other serine/threonine kinases. The compound has been widely used in biochemical research to study PKC-mediated signaling pathways and cellular processes such as superoxide release from human neutrophils. Its mechanism involves competitive inhibition at the ATP-binding site of PKC enzymes. While it has significant value as a pharmacological tool in laboratory settings, there is no evidence that it has been developed or approved for clinical use in humans[6][8][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.